FDA Approval Alert: The Need-to-Know | Dostarlimab Plus Chemotherapy in Advanced dMMR/MSI-H Endometrial Cancer

In July 2023, the FDA approved dostarlimab plus chemotherapy as a frontline treatment option for patients with primary advanced or recurrent mismatch repair deficient or microsatellite instability–high endometrial cancer.

Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
‘Unprecedented’ Results Support Dostarlimab Approval in Endometrial Cancer
Video
Aug 3, 2023 8:00 PM
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.
FDA Approves Dostarlimab in Advanced dMMR/MSI-H Endometrial Cancer
Article
Jul 31, 2023 7:24 PM
Findings from the phase 3 RUBY trial support the FDA’s approval of dostarlimab/chemotherapy as a treatment for advanced or recurrent endometrial cancer that is either mismatch repair deficient or microsatellite instability–high.